c-Fos Antibody, anti-mouse, REAfinity™
Synonyms: p55, AP-1, FOS
RECOMBINANT
Clone:
REA1528 | 9F6
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1
Applications:
3D-IF, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »

Related products for c-Fos Antibody, anti-mouse, REAfinity™

3D-Immunofluorescence applications
Vio R667
Tissue clearing:
MACS® Deep Clearing Kit
Fixation:
PFA
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
Vio R667
Used products:
130-142-364
Description:
3D-immunofluorescence analysis of mouse brain hemisphere fixed with 4% PFA and subjected to whole-mount immunostaining with c-Fos Antibody, anti-human/anti-mouse/anti-rat, Vio® R667 (red). The sample was processed and optically cleared using the MACS® Deep Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. The image was processed using Destripe and Contrast Compression in MACS iQ View – 3D Large Volume Software. Sample detail image (A), overview of sample (B) showing immunostaining using c-Fos Vio® R667 (red) and hemisphere autofluorescence (grey), 3D-rendered maximum intensity projection (C) and 3D-rendered video (D). Scale bars: 100 µm (A), 500 µm (B), 150 µm (C). Glioblastoma mouse model was kindly provided by Marie Catherine Tiveron and Harold Cremer (Aix-Marseille Université, CNRS, IBDM, Marseille, France).

A

Application imageView details view details

B

Application imageView details view details

C

Application imageView details view details
Specifications for c-Fos Antibody, anti-mouse, REAfinity™
Overview

Clone REA1528 recognizes c-Fos, a nuclear phosphoprotein that is part of the AP-1 (“activator protein-1”) transcription factor complex, which regulates gene expression. c-Fos is expressed in many cell types, particularly in cells undergoing proliferation, differentiation, or response to signals. c-Fos is often overexpressed in tumors, e.g., in osteosarcomas, head and neck squamous cell carcinoma, and other types of cancer. Overexpression correlates with characteristics such as increased proliferation, migration, invasive behavior, and the ability of cells to behave like cancer stem cells. c-Fos controls cell growth, differentiation, events such as mitogen-induced responses and stress responses, and also influences apoptosis and survival. In many types of cancer, c-Fos contributes to tumor progression, resistance to therapies, and suppression of the immune system response. It is therefore an interesting target for cancer therapies, e.g., through inhibitors of the AP-1 complex, through modulation of c-Fos in therapeutic immune cells, or in combination with other therapies to overcome resistance.

Alternative names

p55, AP-1, FOS

Detailed product information

Technical specifications

Clone
REA1528
Clonality
monoclonal
Isotype
recombinant human IgG1
Host
cell line
Type of antibody
Recombinant antibodies, Primary antibodies
Species reactivity
mouse
Antigen
c-Fos

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for c-Fos Antibody, anti-mouse, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for c-Fos Antibody, anti-mouse, REAfinity™
Publications
  1. Wang, Q. et al. (2017) Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9. PLoS One 12 (6): e0180558
  2. Croushore, E. E. et al. (2023) Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress. Cancer Res Commun 3 (8): 1580-1593
  3. Wu, J. X. et al. (1990) The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5 (7): 989-1000

You have previously chosen International as your location.
What do you want to do?